Activating T cells by suppressing the PD-1/PD-L1 pathway with immune checkpoint inhibitors induces autoimmune-disease-like-symptoms in cancer patients, but it is still under investigation as to how the activation of pathways of Th17 or Tregs affects the phenotypes in CIA and CAIA. This evidence concerns the gene PDCD1 and autoimmune disease.